Next‐Gen biotherapeutics: A systematic review and network meta‐analysis on postbiotics as treatment for pediatric atopic dermatitis
Pediatric Allergy and Immunology · 2023-09 · 34 (9)
DOI: 10.1111/pai.14022 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Pediatric Allergy and Immunology, online erschienen am 21.09.2023. Verfasst von Carol Stephanie C Tan Lim und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Epidemiology, College of Medicine, University of the Philippines Manila, Manila, Philippines. Hauptthemen laut MEDLINE: Dermatitis, Atopic, Lacticaseibacillus paracasei, Lacticaseibacillus rhamnosus. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 38 Literaturangaben.
Abstract (Originalsprache)
Background
Due to the recency of the postbiotic field, no head‐to‐head postbiotic studies have investigated its biotherapeutic potential for atopic dermatitis (AD). No network meta‐analysis (NMA) has been conducted to synthesize relevant studies comparing postbiotic interventions for AD.
Objective
To assess the comparative efficacy and safety of postbiotic strains in the treatment of pediatric AD. Methodology This was an NMA of randomized controlled studies that evaluated postbiotics in treating pediatric AD. Systematic search of databases and registers from inception to November 30, 2022. Three authors independently performed the search, screening, and appraisal using the Cochrane risk‐of‐bias tool version 2 and data extraction. Data analysis was performed using STATA14 software.
Results
Nine studies evaluated eight postbiotic preparations. Lactobacillus rhamnosus IDCC 3201 (LR) ranked highest in the efficacy outcome. Compared to placebo, LR may be effective in reducing symptoms of atopic dermatitis in the main analysis (SMD −0.53, 95%CI −1.02 to −0.04) and sensitivity analysis involving studies that used SCORAD (MD −5.52, 95% CI −10.46 to −0.58), based on low‐certainty evidence. Based on moderate‐certainty evidence, LR probably did not increase the risk of adverse events (RR 0.97, 95% CI 0.79, 1.21). Although Lactobacillus paracasei GM080 (LP2) ranked highest in the safety outcome, it may not reduce AD symptoms compared to placebo (SMD −0.03, 95% CI −0.37, 0.32) based on low‐certainty evidence.
Conclusion
LR showed significant benefits in children with AD based on low‐certainty evidence. Further investigation of LR is recommended.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Clinical Epidemiology, College of Medicine, University of the Philippines Manila, Manila, Philippines.
- Department of Biology, College of Science, University of the Philippines Baguio, Baguio City, Philippines.
ORCID-Profile: Carol Stephanie C Tan Lim, Ma Easter Joy V Sajo, Khianne Ed Miguel P Orteza
Zitieren
APA
Tan Lim, C. S. C., Sajo, M. E. J. V., Orteza, K. E. M. P., Fernandez, P. B. A., & Vila, M. J. C. (2023). Next‐Gen biotherapeutics: A systematic review and network meta‐analysis on postbiotics as treatment for pediatric atopic dermatitis. Pediatric Allergy and Immunology, 34(9). https://doi.org/10.1111/pai.14022
Vancouver
Tan Lim CSC, Sajo MEJV, Orteza KEMP, Fernandez PBA, Vila MJC. Next‐Gen biotherapeutics: A systematic review and network meta‐analysis on postbiotics as treatment for pediatric atopic dermatitis. Pediatric Allergy and Immunology. 2023;34(9). doi:10.1111/pai.14022
BibTeX
@article{TanLim2023,
author = {Tan Lim, Carol Stephanie C and Sajo, Ma Easter Joy V and Orteza, Khianne Ed Miguel P and Fernandez, Patricia Barbara A and Vila, Ma Junella C},
title = {Next‐Gen biotherapeutics: A systematic review and network meta‐analysis on postbiotics as treatment for pediatric atopic dermatitis},
journal = {Pediatric Allergy and Immunology},
year = {2023},
volume = {34},
number = {9},
doi = {10.1111/pai.14022}
}
EUVIMED